EUVIMEDEUVIMED entdecken
Crossref

Sales Erosion of Originator Drugs Following Generic Entry: Quantitative Analysis and Predictive Modeling

Soon Kyu Jung, Sang-Won Lee

Therapeutic Innovation & Regulatory Science · 2026

DOI: 10.1007/s43441-025-00878-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2026. Verfasst von Soon Kyu Jung und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon, Gyeonggi-do, 16419, Republic of Korea. Hauptthemen laut MEDLINE: Drugs, Generic, Commerce, Drug Industry. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Generic drug entry into the pharmaceutical market typically leads to a substantial decline in originator sales. Understanding the extent and trajectory of this erosion is essential for effective lifecycle management and strategic planning. This study quantified sales erosion after generic entry for originator drugs approved in the United States between 2010 and 2019 and developed a model to predict year-specific sales retention based on key product- and market-level characteristics. METHODS: A total of 140 originator drugs were analyzed using FDA approval records and sales data from Evaluate Pharma. Five-year retention patterns were modeled using a three-parameter exponential decay function. Subgroup analyses were conducted by year of generic entry, therapeutic class, and product-specific features. A polynomial regression model using 700 product-year observations incorporated three binary market indicators and linear and quadratic time terms. RESULTS: Sales retention declined from 73.1% in the first year after generic entry to 31.7% by year five. The exponential decay model demonstrated a strong goodness-of-fit (root mean squared error [RMSE] = 0.006), capturing the initial steep decline and subsequent stabilization. Subgroup analyses showed faster erosion for blockbuster drugs and in markets with multiple first-generation generics. The regression model explained 96.4% of annual variation in retention (RMSE = 0.033), accounting for product and market heterogeneity. CONCLUSION: Sales decline after generic entry follows a predictable yet heterogeneous trajectory shaped by product and market factors. Exponential decay and polynomial regression models together offer a robust framework for forecasting sales retention and guiding strategic decisions in the pharmaceutical industry.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drugs, GenericCommerceDrug IndustryUnited StatesHumansDrug Approval

Stichwörter der Autor:innen

Exponential decayGeneric entryPolynomial regressionPost-exclusivity dynamicsSales erosion

Substanzen

Drugs, Generic

Autor:innen und Institutionen

  • School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon, Gyeonggi-do, 16419, Republic of Korea.
  • Korea Health Industry Development Institute, Osong, Republic of Korea.
  • School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon, Gyeonggi-do, 16419, Republic of Korea. sangwlee@skku.edu.

Zitieren

APA

Jung, S. K., & Lee, S. W. (2026). Sales Erosion of Originator Drugs Following Generic Entry: Quantitative Analysis and Predictive Modeling. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-025-00878-9

Vancouver

Jung SK, Lee SW. Sales Erosion of Originator Drugs Following Generic Entry: Quantitative Analysis and Predictive Modeling. Therapeutic Innovation & Regulatory Science. 2026. doi:10.1007/s43441-025-00878-9

BibTeX
@article{Jung2026,
  author = {Jung, Soon Kyu and Lee, Sang-Won},
  title = {Sales Erosion of Originator Drugs Following Generic Entry: Quantitative Analysis and Predictive Modeling},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2026},
  doi = {10.1007/s43441-025-00878-9}
}
Kostenlos starten →